AstraZeneca said its COVID-19 vaccine Covishield was effective against the Omicron coronavirus variant after the third dose in one study, with the same level of neutralization as the Delta variant after the regular two-dose course.
AstraZeneca’s Vaxjeveria significantly increased antibody levels against the Omicron SARS-CoV-2 variant (B.1.1.529) after a third-dose booster, according to data from a new laboratory study.
Neutralization levels for Omicron were increased after the third dose with VAXZEVARIA compared to titers after the second dose. The company said that the third dose booster was observed after exceeding the neutralizing antibodies found in individuals who had previously been naturally infected and recovered from COVID-19 (alpha, beta, delta variants and original strains).
Sera obtained from individuals one month after receiving the third dose booster vaccination neutralized the Omicron variant to levels that were broadly similar to those seen one month after the second dose against the delta variant.
The study analyzed blood samples taken from individuals infected with COVID-19; people who were vaccinated with a two-dose schedule and a third-dose booster; and those who reported previous infection with other COVID-19 forms of concern. The study included a sample of 41 individuals who had received three doses of Vaxgevaria.
The study was carried out independently by investigators at the University of Oxford.
The results are largely good news for the vaccine.
Astra shares rose 0.3% in early London trading.
omicronThe rapid spread of the disease and its ability to initially reduce antibody protection in many vaccines prompted many countries to launch rapid booster campaigns.
Never miss a story! Stay connected and informed with Mint.
download
Our App Now!!
,